ThermImage was incorporated in February 2007 to commercialize the MicroSense™ radiometric temperature measurement system, a unique and proprietary platform technology that provides direct temperature measurement of tissues deep within the body. The first embodiment of this technology is the AccuCor DTMS™ (Deep Tissue Monitoring System), which is designed to monitor actual brain temperature accurately, continuously, and non-invasively. This system is expected to gain rapid acceptance for monitoring and managing patients placed on a heart-lung machine for cardiac surgery, patients undergoing induced hypothermia for any reason, patients in neurological ICUs, patients in pediatric and neonatal ICUs, patients presenting in emergency departments, and many patients undergoing non-cardiac surgery. The company estimates the total worldwide market potential for this application to be in excess of $3.5 billion. The second embodiment of the MicroSense™ technology is a system that meets the pressing need for a safe and non-invasive means of diagnosing pediatric Vesicoureteral Reflux (VUR), a condition in which bladder urine flows back up into the kidneys, exposing them to infection and potential lifelong health problems. Using the most conservative published VUR incidence rate of one percent, there are more than 840,000 new cases of VUR diagnosed annually. The company estimates the total worldwide market potential for this application to be in excess of $1.0 billion.